BACKGROUND: Alterations in the highly penetrant cancer susceptibility gene BRCA1 are responsible for the majority of hereditary breast and/or ovarian cancers. However, the number of detected germline mutations has been lower than expected based upon genetic linkage data. Undetected deleterious mutations in the BRCA1 gene in some high-risk families could be due to the presence of intragenic rearrangements as deletions, duplications or insertions spanning whole exons. Standard PCR-based screening methods are mainly focused on detecting point mutations and small insertions/deletions, but large rearrangements might escape detection.The purpose of this study was to determine the type and frequency of large genomic rearrangements in the BRCA1 gene in hereditary breast and ovarian cancer cases in the Czech Republic. METHODS: Multiplex ligation-dependent probe amplification (MLPA) was used to examine BRCA1 rearrangements in 172 unrelated patients with hereditary breast and/or ovarian cancer syndrome without finding deleterious mutation after complete screening of whole coding regions of BRCA1/2 genes. Positive MLPA results were confirmed and located by long-range PCR. The breakpoints of detected rearrangements were characterized by sequencing. RESULTS: Six different large deletions in the BRCA1 gene were identified in 10 out of 172 unrelated high-risk patients: exons 1A/1B and 2 deletion; partial deletion of exon 11 and exon 12; exons 18 and 19 deletion; exon 20 deletion; exons 21 and 22 deletion; and deletion of exons 5 to 14. The breakpoint junctions were localized and further characterized. Destabilization and global unfolding of the mutated BRCT domains explain the molecular and genetic defects associated with the exon 20 in-frame deletion and the exon 21 and 22 in-frame deletion, respectively. CONCLUSION: Using MLPA, mutations were detected in 6% of high-risk patients previously designated as BRCA1/2 mutation-negative. The breakpoints of five out of six large deletions detected in Czech patients are novel. Screening for large genomic rearrangements in the BRCA1 gene in the Czech high-risk patients is highly supported by this study.

Masaryk Memorial Cancer Institute Brno Czech Republic

Zobrazit více v PubMed

Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci USA. 1988;85:3044–3048. doi: 10.1073/pnas.85.9.3044. PubMed DOI PMC

Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Sobol H, Teare MD, Strueving J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjor J, Lynch H, Ponder BAJ, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M, the Breast Cancer Linkage Consortium Genetic heterogeneity and penetrance of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676–689. doi: 10.1086/301749. PubMed DOI PMC

Breast Cancer Information Core internet web site

Armour JAL, Barton DE, Cockburn DJ, Taylor GR. The detection of large deletions or duplications in genomic DNA. Hum Mutat. 2002;20:325–327. doi: 10.1002/humu.10133. PubMed DOI

Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ, van 't Veer LJ, Bakker E, van Ommen GJ, Devilee P. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997;17:341–345. doi: 10.1038/ng1197-341. PubMed DOI

Swensen J, Hoffman M, Skolnick MH, Neuhausen SL. Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family. Hum Mol Genet. 1997;6:1513–1517. doi: 10.1093/hmg/6.9.1513. PubMed DOI

Puget N, Stoppa-Lyonet D, Sinilnikova OM, Pages S, Lynch HT, Lenoir GM, Mazoyer S. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res. 1999;59:455–461. PubMed

Rohlfs EM, Chung CH, Yang Q, Skrzynia C, Grody WW, Graham ML, Silverman LM. In-frame deletions of BRCA1 may define critical functional domains. Hum Genet. 2000;107:385–390. doi: 10.1007/s004390000372. PubMed DOI

Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, Lenoir GM, Mazoyer S, Weber BL. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000;67:841–850. doi: 10.1086/303076. PubMed DOI PMC

Payne SR, Newman B, King MC. Complex germline rearrangements of BRCA1 associated with breast and ovarian cancer. Genes Chromosomes Cancer. 2000;29:58–62. doi: 10.1002/1098-2264(2000)9999:9999<::AID-GCC1008>3.0.CO;2-F. PubMed DOI

Gad S, Aurias A, Puget N, Mairal A, Schurra C, Montagna M, Pages S, Caux V, Mazoyer S, Bensimon A, Stoppa-Lyonnet D. Color bar coding the BRCA1 gene on combed DNA: a useful strategy for detecting large gene rearrangements. Genes Chromosomes Cancer. 2001;31:75–84. doi: 10.1002/gcc.1120. PubMed DOI

Gad S, Klinger M, Caux-Moncoutier V, Pages-Berhouet S, Gauthier-Villars M, Coupier I, Bensimon A, Aurias A, Stoppa-Lyonnet D. Bar code screening on combed DNA for large rearrangements of the BRCA1 and BRCA2 genes in French breast cancer families. J Med Genet. 2002;39:817–821. doi: 10.1136/jmg.39.11.817. PubMed DOI PMC

Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa-Lyonnet D, Frebourg T, Tosi M. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat. 2002;20:218–226. doi: 10.1002/humu.10108. PubMed DOI

Hofmann W, Görgens H, John A, Horn D, Hüttner Ch, Arnold N, Scherneck S, Schackert HK. Screening for large rearrangements of the BRCA1 gene in German breast or ovarian cancer families using semi-quantitative multiplex PCR method. Hum Mutat. 2003;22:103–104. doi: 10.1002/humu.9154. PubMed DOI

Barrois M, Bieche I, Mazoyer S, Champeme MH, Bressac de-Paillerets B, Lidereau R. Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families. Clin Genet. 2004;65:131–136. doi: 10.1111/j.0009-9163.2004.00200.x. PubMed DOI

Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57. doi: 10.1093/nar/gnf056. PubMed DOI PMC

Mazoyer S. Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat. 2005;25:415–422. doi: 10.1002/humu.20169. PubMed DOI

Smith TM, Lee MK, Szabo CI, Jerome N, McEuen M, Taylor M, Hood L, King MC. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res. 1996;6:1029–1049. doi: 10.1101/gr.6.11.1029. PubMed DOI

Puget N, Gad S, Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot. Am J Hum Genet. 2002;70:858–865. doi: 10.1086/339434. PubMed DOI PMC

Gad S, Caux-Moncoutier V, Pages-Berhouet S, Gauthier-Villars M, Coupier I, Pujol P, Frenay M, Gilbert B, Maugard C, Bignon YJ, Chevrier A, Rossi A, Fricker JP, Nguyen TD, Demange L, Aurias A, Bensimon A, Stoppa-Lyonnet D. Significant contribution of large genomic rearrangements in 120 French breast cancer families. Oncogene. 2002;21:6841–6847. doi: 10.1038/sj.onc.1205685. PubMed DOI

Hartmann C, John AL, Klaes R, Hofmann W, Bielen R, Koehler R, Janssen B, Bartram CR, Arnold N, Zschocke J. Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families. Hum Mutat. 2004;24:534. doi: 10.1002/humu.9291. PubMed DOI

Woodward AM, Davis TA, Silva AG, Kirk JA, Leary JA, kConFab Investigators Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. J Med Genet. 2005;42:e31. doi: 10.1136/jmg.2004.027961. PubMed DOI PMC

de la Hoya M, Gutierrez-Enriquez S, Velasco E, Osorio A, de Abajo AS, Vega A, Salazar R, Esteban E, Llort G, Gonzalez-Sarmiento R, Carracedo A, Benitez J, Miner C, Diez O, Diaz-Rubio E, Caldes T. Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer. Clinical Chemistry. 2006;52:1480–1485. doi: 10.1373/clinchem.2006.070110. PubMed DOI

Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative Method. Cancer Res. 2003;63:1449–1453. PubMed

Montagna M, Dalla Palma M, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L, D'Andrea E. Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum Mol Genet. 2003;12:1055–1061. doi: 10.1093/hmg/ddg120. PubMed DOI

Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet. 2002;11:2805–2814. doi: 10.1093/hmg/11.23.2805. PubMed DOI

Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003;348:2339–2347. doi: 10.1056/NEJMra012284. PubMed DOI

Foretova L, Machackova E, Navratilova M, Pavlu H, Hruba M, Lukesova M, Valik D. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Hum Mutat. 2004;23:397–398. doi: 10.1002/humu.9226. PubMed DOI

MRC-Holland

GeneFisher – Interactive PCR Primer Design

RepeatMasker Web Server

Antonarakis SE, the Nomenclature Working Group Recommendations for a nomenclature system for human gene mutations. Hum Mutat. 1998;11:1–3. doi: 10.1002/(SICI)1098-1004(1998)11:1<1::AID-HUMU1>3.0.CO;2-O. PubMed DOI

Williams RS, Green R, Glover JN. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol. 2001;8:838–842. doi: 10.1038/nsb1001-838. PubMed DOI

Joo WS, Jeffrey PD, Cantor SB, Finnin MS, Livingston DM, Pavletich NP. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the BRCA1 BRCT structure. Genes Dev. 2002;16:583–593. doi: 10.1101/gad.959202. PubMed DOI PMC

Shiozaki EN, Gu L, Yan N, Shi Y. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. Mol Cell. 2004;14:405–412. doi: 10.1016/S1097-2765(04)00238-2. PubMed DOI

Williams RS, Lee MS, Hau DD, Glover JN. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol. 2004;11:519–525. doi: 10.1038/nsmb776. PubMed DOI

Varma AK, Brown RS, Birrane G, Ladias JA. Structural basis for cell cycle checkpoint control by the BRCA1 -CtIP complex. Biochemistry. 2005;44:10941–10946. doi: 10.1021/bi0509651. PubMed DOI

Clapperton JA, Manke IA, Lowery DM, Ho T, Haire LF, Yaffe MB, Smerdon SJ. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol. 2004;11:512–518. doi: 10.1038/nsmb775. PubMed DOI

Belogianni I, Apessos A, Mihalatos M, Razi E, Labropoulos S, Petounis A, Gaki V, Keramopoulos A, Pandis N, Kyriacou K, Hadjisavvas A, Kosmidis P, Yannoukakos D, Nasioulas G. Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer. BMC Cancer. 2004;4:61. doi: 10.1186/1471-2407-4-61. PubMed DOI PMC

Preisler-Adams S, Schönbuchner I, Fiebig B, Welling B, Dworniczak B, Weber BH. Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin. Cancer Genet Cytogenet. 2006;168:44–49. doi: 10.1016/j.cancergencyto.2005.07.005. PubMed DOI

Thompson D, Easton D, Breast Cancer Linkage Consortium Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev. 2002;11:329–336. PubMed

Montagna M, Agata S, De Nicolo A, Menin C, Sordi G, Chieco-Bianchi L, D'Andrea E. Identification of BRCA1 and BRCA2 by carriers by allele-specific gene expression (AGE) analysis. Int J Cancer. 2002;98:732–736. doi: 10.1002/ijc.10273. PubMed DOI

Deng CX, Brodie SG. Roles of BRCA1 and its interacting proteins. Bioessays. 2000;22:728–737. doi: 10.1002/1521-1878(200008)22:8<728::AID-BIES6>3.0.CO;2-B. PubMed DOI

Williams RS, Chasman DI, Duong Hau D, Hui B, Lau AY, Glover JNM. Detection of protein folding defects caused by BRCA1 -BRCT truncation and missense mutations. J Biol Chem. 2003;278:53007–53016. doi: 10.1074/jbc.M310182200. PubMed DOI

Williams RS, Green R, Glover JNM. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol. 2001;8:838–842. doi: 10.1038/nsb1001-838. PubMed DOI

Williams RS, Glover JNM. Structural consequences of a cancer-causing BRCA1 -BRCT missense mutation. J Biol Chem. 2003;278:2630–2635. doi: 10.1074/jbc.M210019200. PubMed DOI

Lahti-Domenici J, Rapakko K, Paakkonen K, Allinen M, Nevenlinna H, Kujala M, Huusko P, Wingwist R. Exclusion of large deletions and other rearrangementsin BRCA1 and BRCA2 in Finnish breast and ovarian cancer families. Cancer Genet Cytogenet. 2001;129:120–123. doi: 10.1016/S0165-4608(01)00437-X. PubMed DOI

Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer